A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

What Was Tested

This registered phase 3 trial tested Retatrutide.

Participation in the study will last about 113 weeks.

It had three arms (groups): one (experimental), one (experimental) and one (experimental).

Participants will receive retatrutide subcutaneously (SC).

Participants will receive retatrutide SC.

Participants will receive retatrutide SC.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 600 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a Body Mass Index (BMI) at screening. ≥ 30 kilogram per square meter (kg/m2) OR. ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease. Have at least one unsuccessful attempt to lose weight by dieting.

The full record lists 4 inclusion and 11 exclusion criteria; among the exclusions: have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening; have a prior or planned surgical treatment for obesity; have type 1 diabetes or type 2 diabetes.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Retatrutide group and the comparison group should start out alike.

The Retatrutide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Retatrutide.

Those kept unaware of assignments: participant and investigator.

It started in 2026-01-24 with completion listed for 2028-10.

It ran at 35 sites in United States (20), Canada (10) and Argentina (5).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percent Change from Baseline in Body Weight (time frame: Baseline, Week 104).

It also tracked 7 secondary outcomes, for example Change from Baseline in Waist Circumference, Percent Change from Baseline in Triglycerides, Change from Baseline in Systolic Blood Pressure, Percent Change from Baseline in High Sensitivity C-Reactive Protein, Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score and Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Retatrutide in 600 people.

With 600 participants it is a large trial for this field.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, all human trials.